SG11202105152YA - Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof - Google Patents

Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof

Info

Publication number
SG11202105152YA
SG11202105152YA SG11202105152YA SG11202105152YA SG11202105152YA SG 11202105152Y A SG11202105152Y A SG 11202105152YA SG 11202105152Y A SG11202105152Y A SG 11202105152YA SG 11202105152Y A SG11202105152Y A SG 11202105152YA SG 11202105152Y A SG11202105152Y A SG 11202105152YA
Authority
SG
Singapore
Prior art keywords
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
SG11202105152YA
Inventor
Eunyoung Park
Yangsoon Lee
Hyejin Chung
Eunsil Sung
Jiseon Yoo
Minji Park
Yong-Gyu Son
Hyoju Choi
Eunjung Kim
Jaeho Jung
Weon-Kyoo You
Sang Hoon Lee
Lei Fang
Wenqing Jiang
Original Assignee
Abl Bio Inc
I Mab Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc, I Mab Biopharma Co Ltd filed Critical Abl Bio Inc
Publication of SG11202105152YA publication Critical patent/SG11202105152YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202105152YA 2018-11-30 2019-02-15 Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof SG11202105152YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773239P 2018-11-30 2018-11-30
PCT/CN2019/075180 WO2020107715A1 (en) 2018-11-30 2019-02-15 Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11202105152YA true SG11202105152YA (en) 2021-06-29

Family

ID=70852440

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105152YA SG11202105152YA (en) 2018-11-30 2019-02-15 Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof

Country Status (18)

Country Link
US (2) US20220056136A1 (en)
EP (2) EP3891187A4 (en)
JP (2) JP7328658B2 (en)
KR (2) KR20210099052A (en)
CN (2) CN113286825B (en)
AU (2) AU2019390274A1 (en)
BR (2) BR112021010402A2 (en)
CA (2) CA3121562A1 (en)
CL (1) CL2021001368A1 (en)
CO (1) CO2021006911A2 (en)
EA (1) EA202191457A1 (en)
IL (1) IL283530A (en)
MX (1) MX2021006379A (en)
PE (1) PE20211778A1 (en)
PH (1) PH12021551171A1 (en)
SG (1) SG11202105152YA (en)
WO (2) WO2020107715A1 (en)
ZA (1) ZA202102870B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059769B2 (en) * 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
JP7124257B2 (en) * 2018-03-29 2022-08-24 アイ－エムエービー バイオファーマ ユーエス リミテッド ANTI-PD-L1 ANTIBODY AND USES THEREOF
BR112022001336A8 (en) * 2019-07-26 2023-02-07 Abl Bio Inc BISPECIFIC ANTI-HER2/ANTI-4-1BB ANTIBODY AND USE OF IT
US20210024638A1 (en) * 2019-07-26 2021-01-28 Abl Bio Inc. Anti-egfr/anti-4-1bb bispecific antibody and use thereof
PE20211147A1 (en) * 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BI-SPECIFIC ANTIBODIES AND THEIR USE
WO2021068841A1 (en) 2019-10-11 2021-04-15 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1bb and uses thereof
KR20230013125A (en) * 2020-06-30 2023-01-26 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 4-1BB Binding Proteins and Uses Thereof
EP4155318A4 (en) * 2020-06-30 2024-06-05 Harbour Biomed US, Inc. Bispecific antibody and use thereof
WO2022039490A1 (en) * 2020-08-18 2022-02-24 Abl Bio, Inc. Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof
CN114195900B (en) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 Anti-4-1 BB/PD-L1 bispecific antibody and application thereof
KR20230128482A (en) * 2020-12-07 2023-09-05 젠맵 에이/에스 Combination therapy of antibodies and taxanes
JP2024502371A (en) * 2021-01-11 2024-01-18 ユーティレックス カンパニー リミテッド Bispecific epitope binding protein comprising anti-4-1BB antibody and PD-1 protein or fragment thereof and uses thereof
KR20220107968A (en) * 2021-01-25 2022-08-02 주식회사유한양행 Methods for purifying an anti-4-1BB/anti-HER2 bispecific antibody
WO2023000675A1 (en) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 Bispecific antibody targeting pd-l1 and 4-1bb
CN114736303A (en) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 Bifunctional antibody for resisting PD-L1 and 4-1BB and medical application thereof
WO2023200865A2 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Cancer therapy
WO2024008032A1 (en) * 2022-07-06 2024-01-11 Beijing Hanmi Pharmaceutical Co., Ltd. Formulations for anti-pd-l1/anti-4-1bb bispecific antibodies
WO2024104373A1 (en) * 2022-11-15 2024-05-23 I-Mab Biopharma Co., Ltd. Anti-pd-l1 nanobodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1539237A4 (en) 2002-07-30 2006-05-24 Bristol Myers Squibb Co Humanized antibodies against human 4-1bb
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
RU2710717C2 (en) 2010-09-09 2020-01-10 Пфайзер Инк. Molecules which bind to 4-1bb
EP3536708A1 (en) * 2011-04-19 2019-09-11 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
KR102060540B1 (en) * 2013-04-03 2019-12-31 삼성전자주식회사 Pharmaceutical composition for a combination therapy containing an anti-c-Met antibody and anti-Ang2 antibody
ES2952717T3 (en) * 2014-10-14 2023-11-03 Novartis Ag Antibody molecules against PD-L1 and uses thereof
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN107921104A (en) * 2015-02-22 2018-04-17 索伦托治疗有限公司 With reference to the antibody therapy of CD137
JP6845846B6 (en) 2015-09-22 2021-04-21 ディンフー バイオターゲット カンパニー リミテッド Fully human antibody of anti-human CD137 and its use
SG10201912405TA (en) * 2016-01-11 2020-02-27 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins
WO2017181034A1 (en) * 2016-04-14 2017-10-19 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
CA3021618A1 (en) * 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
WO2017205745A1 (en) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
CN107488229B (en) * 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 PD-L1 antibodies and uses thereof
US10059769B2 (en) 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
CN109475602B (en) * 2016-06-20 2023-05-16 科马布有限公司 anti-PD-L1 and IL-2 cytokines
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102089072B1 (en) * 2017-01-06 2020-03-17 주식회사 유틸렉스 Anti-human 4-1BB antibody and use thereof
CN107326014B (en) * 2017-07-31 2019-09-24 时力生物科技（北京）有限公司 A kind of T lymphocyte and its preparation method and application of bispecific chimeric antigen receptor modification
WO2019225787A1 (en) * 2018-05-24 2019-11-28 에이비엘바이오 주식회사 Anti-b7-h3 antibody and use thereof

Also Published As

Publication number Publication date
PE20211778A1 (en) 2021-09-08
AU2019390274A1 (en) 2021-07-22
US20220056136A1 (en) 2022-02-24
CN113166250A (en) 2021-07-23
CA3121562A1 (en) 2020-06-04
CA3121218A1 (en) 2020-06-04
EP3887403A1 (en) 2021-10-06
PH12021551171A1 (en) 2021-11-29
AU2019386549A1 (en) 2021-06-24
CL2021001368A1 (en) 2022-03-04
JP7378474B2 (en) 2023-11-13
WO2020111913A1 (en) 2020-06-04
KR20210099052A (en) 2021-08-11
EP3887403A4 (en) 2022-08-31
EP3891187A1 (en) 2021-10-13
JP2022513694A (en) 2022-02-09
KR20210087094A (en) 2021-07-09
CN113286825A (en) 2021-08-20
JP2022510253A (en) 2022-01-26
CN113286825B (en) 2024-06-18
BR112021010394A2 (en) 2021-08-24
WO2020107715A1 (en) 2020-06-04
ZA202102870B (en) 2023-05-31
AU2019386549B2 (en) 2024-07-25
EP3891187A4 (en) 2022-10-05
MX2021006379A (en) 2021-10-13
IL283530A (en) 2021-07-29
CN113166250B (en) 2023-10-03
BR112021010402A2 (en) 2021-08-24
CO2021006911A2 (en) 2021-08-09
EA202191457A1 (en) 2021-09-06
US20220242961A1 (en) 2022-08-04
JP7328658B2 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
IL283530A (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
IL279974A (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
IL279354A (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
IL283493A (en) Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
IL289946A (en) Bispecific antibodies against cd3 and cd20
IL279235A (en) Dll3-cd3 bispecific antibodies
EP3889174A4 (en) Homodimer-type bispecific antibody against her2 and cd3 and use thereof
IL279455A (en) Anti-pd-1 antibodies and uses thereof
HK1258304A1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
IL283945A (en) Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
IL278846A (en) Anti-cd3 antibodies and uses thereof
IL290255A (en) Anti-ctla4/anti-pd-1 bispecific antibody and use thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL277968A (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3833693A4 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
ZA202004908B (en) Bispecific antibody
IL269645A (en) Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
IL276675A (en) Anti-pd-1 antibodies and uses thereof
IL278862A (en) Monospecific and multispecifc anti-tmeff2 antibodies and their uses
IL283180A (en) Anti-pd-1 antibodies and uses thereof
IL282355A (en) Exosome-targeting bispecific antibodies
ZA202003858B (en) Monoclonal antibodies and methods for using same
GB201910138D0 (en) Anti-pd-l1 antibodies